Dr. Gabrielle T. Prince

Dr. B. Douglas Smith is an Oncologist in Baltimore caring for patients with leukemias and other blood and bone marrow disorders and he is recognized nationally as an expert in the care of patients with these disorders and as a leader in novel therapeutics for these conditions. Dr. Smith serves as the Co-Director of Clinical Research Operations for the Division of Hematologic Malignancies and helps to manage the Division’s clinical research trials. Dr. Smith received his undergraduate degree in Biology from Lafayette College (Easton, PA), earned his M.D. at the Medical College of Pennsylvania (Philadelphia, PA), completed his Residency at Strong Memorial Hospital of the University of Rochester (Rochester, NY), and Fellowship in Medical Oncology at Johns Hopkins (Baltimore, MD). Dr. Smith joined the Johns Hopkins faculty in 1998 at the completion of his training. His main research interests include drug development for patients with AML, CML, and MDS and he serves as Co-Investigator for the Oncology Center’s UM1 (early phase drug development) Grant. The Leukemia Program’s clinical trials portfolio has included trials for each of the 8 newly FDA-approved drugs for acute leukemia in the past 2 years. Dr. Smith has a passion for teaching trainees and has served on the Fellowship Executive Committee since 2010 focusing on the program’s educational platforms. He has won numerous teaching awards in both the Department of Oncology and the Department of Medicine multiple times, and he has a track record of mentoring fellows pursuing clinical-translational research and clinician-educator pathways. In 2020, Dr. Smith was awarded membership in the prestigious Miller Coulson Academy for Excellence in Clinical Care. He is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American Association for Cancer Research. He has served on the National Comprehensive Cancer Network guideline panel for CML since 2001 and previously served on the AML panel from 2001-2015. Dr. Smith has extensive experience in the regulatory aspects of drug development and he currently serves as the Chair of the Johns Hopkins Institutional Review Board #2. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.

Mark J. Levis, M.D., Ph.D., professor of oncology, medicine and pharmacology in the Division of Hematologic Malignancies at the Johns Hopkins University School of Medicine, co-directs the Hematologic Malignancies and Bone Marrow Transplantation Program and directs the Adult Leukemia Service at the Johns Hopkins Sidney Kimmel Cancer Center. In addition to his role within the Kimmel Cancer Center, he serves on the faculty for the Johns Hopkins Graduate Training Program in Cellular and Molecular Medicine, a Ph.D. program that prepares scientists to conduct laboratory research at the cellular and molecular level that is designed to have a direct impact on the understanding of human diseases. Dr. Levis has expertise in acute and chronic myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes. Dr. Levis received his medical degree at the University of California, San Francisco School of Medicine, where he also earned his Ph.D. in Biochemistry. He completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology. Dr. Levis is a member of the American Society of Hematology, the American Society of Clinical Oncology and the European Hematology Association. He is an ad hoc member of the Oncology Drug Advisory Committee, as well as an ad hoc manuscript referee for peer-reviewed journals such as New England Journal of Medicine; Leukemia; Clinical Cancer Research; and The American Journal of Hematology. Dr. Levis has earned numerous awards, such as the Daniel Nathans Research Award from Johns Hopkins University, the Osler Housestaff Teaching Award, the Director's Teaching Award in Clinical Science, and the Advanced Clinical Research Award from the American Society of Clinical Oncology. Dr. Levis’ laboratory research focuses on the development of molecularly-targeted therapies for leukemia. He is actively involved in the pre-clinical and clinical development of small molecule inhibitors of protein kinases, including FLT3. The research involves studying the biochemical effects of these inhibitors on samples taken from leukemia patients, with the broad goal of identifying and validating novel molecular therapeutic targets in these hematopoietic malignancies. While Dr. Levis plays a key role in the pre-clinical development of these therapies, he is particularly interested in translating this research to the bedside of his patients by using correlative studies to incorporate these novel therapies into existing treatments. In addition to his work in both the clinic and the laboratory, Dr. Levis has also conducted talks, mentorship and teaching lectures, and published extensively in the top journals in his field, including Leukemia; Blood; and the New England Journal of Medicine. Dr. Levis is rated as an Elite provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Carole Miller is an Oncologist in Baltimore, Maryland. Dr. Miller is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Familial Colorectal Cancer, and Muscle Invasive Bladder Cancer. Dr. Miller is currently accepting new patients.